OtherBASIC SCIENCE INVESTIGATIONS
131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
Yuni K. Dewaraja, Matthew J. Schipper, Peter L. Roberson, Scott J. Wilderman, Hanan Amro, Denise D. Regan, Kenneth F. Koral, Mark S. Kaminski and Anca M. Avram
Journal of Nuclear Medicine July 2010, 51 (7) 1155-1162; DOI: https://doi.org/10.2967/jnumed.110.075176
Yuni K. Dewaraja
Matthew J. Schipper
Peter L. Roberson
Scott J. Wilderman
Hanan Amro
Denise D. Regan
Kenneth F. Koral
Mark S. Kaminski
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 51, Issue 7
July 2010
131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
Yuni K. Dewaraja, Matthew J. Schipper, Peter L. Roberson, Scott J. Wilderman, Hanan Amro, Denise D. Regan, Kenneth F. Koral, Mark S. Kaminski, Anca M. Avram
Journal of Nuclear Medicine Jul 2010, 51 (7) 1155-1162; DOI: 10.2967/jnumed.110.075176
131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
Yuni K. Dewaraja, Matthew J. Schipper, Peter L. Roberson, Scott J. Wilderman, Hanan Amro, Denise D. Regan, Kenneth F. Koral, Mark S. Kaminski, Anca M. Avram
Journal of Nuclear Medicine Jul 2010, 51 (7) 1155-1162; DOI: 10.2967/jnumed.110.075176
Jump to section
Related Articles
Cited By...
- Dosimetry in Radiopharmaceutical Therapy
- Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
- DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker
- Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
- Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy
- MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
- Advances in Immuno-Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
- MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy
- Tumor Dosimetry and Response for 153Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma
- Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models